Regeneron Pharmaceuticals (REGN) Cash from Investing Activities (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Cash from Investing Activities of -$92.7 million for Q2 2026, up 91.53% year-over-year from -$48.4 million in Q2 2025, and up 78.39% quarter-over-quarter from -$428.9 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$92.7 million for Q2 2026.
- In Q2 2026, Cash from Investing Activities rose 91.53% year-over-year to -$92.7 million; the TTM figure through Jun 2026 stood at -$704.2 million (down 5.06% YoY), while the FY2025 annual figure was -$629.1 million, up 74.51% from the prior year.
- Cash from Investing Activities for Q2 2026 stood at -$92.7 million, up from -$428.9 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $647.5 million in Q1 2025, with the low at -$2.4 billion in Q2 2023.
- The 5-year median for Cash from Investing Activities is -$421.4 million (2022), against an average of -$588.2 million.
- Peak annual rise in Cash from Investing Activities reached 629.61% in 2024, while the deepest fall reached 615.78% in 2024.
- Regeneron Pharmaceuticals' Cash from Investing Activities stood at -$1.9 billion in 2022, then jumped by 96.44% to -$66.2 million in 2023, then soared by 629.61% to $350.6 million in 2024, then tumbled by 37.16% to $220.3 million in 2025, then sank by 142.08% to -$92.7 million in 2026.
- Business Quant data shows REGN's Cash from Investing Activities at -$92.7 million in Q2 2026, -$428.9 million in Q1 2026, and $220.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 281.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -92.70 Mn |
| Jun 30, 2026 | -92.70 Mn |
| Mar 31, 2026 | -428.90 Mn |
| Mar 31, 2026 | -428.90 Mn |
| Dec 31, 2025 | 220.30 Mn |
| Dec 31, 2025 | 220.30 Mn |
| Sep 30, 2025 | -402.90 Mn |
| Sep 30, 2025 | -402.90 Mn |
| Jun 30, 2025 | -1.09 Bn |
| Jun 30, 2025 | -1.09 Bn |
| Mar 31, 2025 | 647.50 Mn |
| Mar 31, 2025 | 647.50 Mn |
| Dec 31, 2024 | 350.60 Mn |
| Dec 31, 2024 | 350.60 Mn |
| Sep 30, 2024 | -574.40 Mn |
| Sep 30, 2024 | -574.40 Mn |
| Jun 30, 2024 | -557.20 Mn |
| Jun 30, 2024 | -557.20 Mn |
| Mar 31, 2024 | -1.69 Bn |
| Mar 31, 2024 | -1.69 Bn |